BM Blokhin*, IP Lobushkova, AS Suyundukova and AD Prokhorova

Department of Outpatient and Emergency Paediatrics, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

*Corresponding Author: BM Blokhin, Department of Outpatient and Emergency Paediatrics, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.

Received: May 24, 2021; Published: June 30, 2021

Abstract

Introduction: The article contains the results of a non-interventional, multicentre, prospective, observational, non-randomized clinical trial evaluating the efficiency and safety of Stodal drug product in children aged 2 to 7 years old with cough caused by acute respiratory infection (ARI).

Objective of the Research: To assess therapeutic efficiency and safety of Stodal drug product in children treated for cough caused by mild to moderate acute respiratory infections.

Materials and Methods: The study included 1000 children aged 2 to 7 years old with cough caused by mild to moderate ARI. The study was conducted in 23 medical institutions based in Moscow and the Moscow region. The study participants were stratified by age into 2 groups: Group 1 included children aged 2 to 4 years old; Group 2 included children aged 4 to 7 years old. Stodal clinical efficiency was evaluated based on the time course of cough severity in the daytime and at night, parents’/adoptive parents' satisfaction with the treatment and the treatment safety. Treatment duration was 7 days.

Results: In both groups, on the 7^th day of therapy, treatment with Stodal resulted in a statistically significant decrease in cough severity: in Group 1, cough severity decreased by 1.51 (from 2.16 to 0.65; p < 0,001); in Group 2 it decreased by 1.57 (from 2.25 to 0.68; p < 0.001). Treatment efficiency was not age-dependent and was similar in both groups (p = 0.158). In total population cough severity in the daytime statistically significantly decreased by 1.53 (from 2.2 on the 1^st day of treatment to 0.67 points on the 7^th day of treatment, p < 0.001). In 35% of patients cough completely resolved (cough severity decreased to 0 points), and in 63% it became clinically insignificant (cough severity was 1 point). These children recovered and were allowed to attend organized groups. In Group 1, nocturnal cough severity statistically significantly decreased by 1.16 (from 1.64 to 0.48, p < 0.001); in Group 2 it decreased by 1.25 (from 1.71 to 0.46, p < 0.001). 951 (95,1%) parents/adoptive parents positively rated cough treatment and scored it using satisfaction rating scale as 4 and 5 points.

Conclusion: The study demonstrated efficiency and safety of Stodal drug product when used for cough treatment in children aged 2 to 7 years old with mild to moderate ARI, which allows to recommend Stodal to be included in treatment regimens beginning from the first days of the disease.

References

1. Pоспотребнадзор. “Сведения об инфекционных и паразитарных заболеваниях за январь-декабрь” (2018)
2. Мелехина ЕВ., et al. “Тактика ведения детей с затяжным кашлевым синдромом после острой инфекции”. Российский вестник перинатологии и педиатрии61 (2016): 110-120.
3. Блохин БМ and Лобушкова ИП. “Лечение кашля при острых респираторных заболеваниях у детей”. Доктор Ру. Педиатрия 5.160 (2019): 15-18.
4. Irwin RS., et al. “Diagnosis and management of cough executive summary ACCP evidence based clinical practice guidelines”. Chest 129 (2006): 1S-23S.
5. Albert RH. “Diagnosis and treatment of acute bronchitis”. American Family Physician 82 (2010): 1345-1350.
6. Morice AH., et al. “Recommendations for the management of cough in adults”. Thorax 61 (2006): i1-24.
7. Jones BF and Stewart MA. “Duration of cough in acute upper respiratory tract infections”. American Family Physician 31 (2002): 971-973.
8. Niimi A., et al. “Impaired cough reflex in patients with recurrent pneumonia”. Thorax 58 (2003): 152-153.
9. Cole AM., et al. “Innate antimicrobial activity of nasal secretions”. Infection and Immunity 67 (1999): 3267-3275.
10. Knowles MR and Boucher RC. “Mucus clearance as a primary innate defense mechanism for mammalian airways”. Journal of Clinical Investigation 109 (2002): 571-577.
11. Wanner A., et al. “Mucociliary clearance in the airways”. American Journal of Respiratory and Critical Care Medicine 154 (1996): 1868-1902.
12. Canning BJ. “Anatomy and neurophysiology of the cough reflex ACCP evidence based clinical practice guidelines”. Chest 129 (2006): 33S-47S.
13. Учайкин ВФ., ред. Диагностика, лечение и профилактика гриппа и острых респираторных заболеваний у детей: пособие для врачей. М., (2001).
14. Мелехина ЕВ., et al. “Тактика ведения детей с затяжным кашлевым синдромом после перенесенного острого респираторного заболевания”. Взгляд врача педиатра-инфекциониста. Журнал Международной Медицины. Педиатрия/ Неонатология 6.17 (2015): 83-88.
15. Локшина ЭЭ., et al. “Опыт применения натуропатического препарата Стодаль у детей с острыми респираторными заболеваниями”. Педиатрия. Журнал им. Г.Н. Сперанского. 95.3 (2016): 158-163.
16. Zanasi A., et al. “Homeopathic medicine for acute caught in upper respiratory tract infections and acute bronchitis: a randomized, double-blind, placebo-controlled trial”. Pulmonary Pharmacology and Therapeutics 1 (2014): 102-108.
17. Геппе НА., et al. “Новое в терапии кашля при острых респираторных заболеваниях в педиатрической практике”. Лечащий врач 9 (2017): 86-90.
18. Короид НВ., et al. “Внебольничные пневмонии у детей: диагностика и лечение. Русский медицинский журнал”. Мать и дитя 22 (2011): 1365-1370.
19. Захарова ИН., et al. “Эффективность препарата Стодаль при кашле у детей на фоне острой респираторной инфекции. Consilium Medicum”. Приложение Педиатрия 1 (2019): 37-43.
20. Селькова ЕП., et al. “Тактика лечения непродуктивного кашля у детей при заболеваниях респираторного тракта вирусной этиологии”. Лечащий врач 8 (2013): 84-88.
21. Likert R. “A Technique for the Measurement of Attitudes. New York: The Science Press, 1932”. Archives of Psychology 140 (1932): 1-55.
22. “Стандартная операционная процедура мониторинга эффективности и безопасности лекарственных препаратов в медицинских организациях государственной системы здравоохранения города Москвы для врачей общей практики и среднего медицинского персонала”. Методические рекомендации № 25. М.В. Журавлева, ред. М.: Департамент здравоохранения города Москвы (2019).

Citation

Citation: BM Blokhin., et al. “Cough Treatment Options in Children with Acute Respiratory Infections".Acta Scientific Nutritional Health 5.7 (2021): 107-117.

Copyright

Copyright: © 2021 BM Blokhin., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.